Searched for
INDIAN PHARMA COMPANIES
Stocks in news: Prime Focus, Groww, GIC RE, Wipro, NykaaIndian benchmark indices traded with a positive bias, with the Nifty consolidating near the 24,000 mark and closing near its day's high. Se...- India has wide AI talent gaps in deployment, governance, security: Quess reportIndia faces significant AI talent gaps in deployment, governance, and security roles, with GenAI deployment showing the widest deficit. Whi...
- How India can win in a rewired global economyIndia is poised to gain from global supply chain shifts. Strategic neutrality and domestic focus are key. The nation must build robust buff...
- Kiran Mazumdar-Shaw eyes crown of world’s top insulin supplier for BioconIndian drugmaker Biocon aims to be the world's top insulin supplier within five years, capitalising on growing demand as major pharmaceutic...
- Indian pharma leaving generics era behind, but the Street hasn't caught up yet: Nandan KulkarniIndian pharma is shifting from generics to innovation. This transformation, extending to 2035, is creating significant new opportunities. C...
- Falling crude, stronger rupee could boost earnings outlook for India: Deepak ShenoyIndian stocks are poised for a favorable period. Falling crude oil prices and a strengthening rupee offer support. Macroeconomic conditions...
- Light at the end of the tunnel? Gautam Shah sees Nifty eyeing 25,500, bets on smallcaps, pharma and Adani stocksIndian equities are nearing a crucial turning point, with market veteran Gautam Shah suggesting a shift in focus beyond benchmark indices. ...
- Why did stock market rally today? Sensex jumps 736 points, Nifty closes above 23,850. 5 key factors behind bull runIndian equities surged nearly 1% as bulls charged through Dalal Street, driven by an Iran-US peace framework and sliding oil prices. The Se...
- Sudip Bandyopadhyay bets on pharma, metals and select cyclicals as geopolitical risks easeEasing West Asia tensions boost global markets, prompting investors to reassess opportunities. Market veteran Sudip Bandyopadhyay favors ph...
- PL Capital cuts Nifty target to 26,449, lists 16 high conviction stock picksAmidst global market turmoil from the Iran-US war and El Nino, PL Capital lowered its Nifty 50 target to 26,449. The brokerage anticipates ...
- 'Not a great environment for Indian market': Harsha Upadhyaya on Iran-US tensions, IT outlook, pharma bet, and where to be cautiousGlobal challenges are impacting Indian stocks. West Asian tensions and rising US inflation create headwinds. Tech sector shifts also affect...
- India needs to remain attractive for innovation-led investment: Judith Love, NovartisWith an eye on India's blossoming market, Novartis is set to launch pioneering therapies, including radioligand and gene therapies. The com...
- Japanese investors are looking beyond China... India is key alternative: Tsutomu Takemura, Senior MD, NomuraIndia is increasingly becoming a long-term structural investment destination rather than a short-term strategic bet. Global capital is movi...
- Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...
- Betting big on mid and smallcaps; largecaps most expensive on PEG basis, says Dinshaw IraniHelios Mutual Fund is shifting investments from large companies to mid and small companies. This move follows earnings growth trends where ...
- SBI in $1 billion funding for Sun Pharma’s US dealState Bank of India is set to commit up to $1 billion to fund Sun Pharmaceutical Industries Ltd.'s $12 billion acquisition of Organon & Co....
- India’s anti-obesity drug market sees slower growth after initial surge in generic semaglutide salesIndia's anti-obesity drug market sees a slowdown after initial generic semaglutide sales. Demand has eased from its peak, with growth moder...
- India willing to open its market to high-quality, innovative pharma products, says commerce ministerIndia is ready to welcome high-quality global pharmaceutical products. This move is in exchange for better market access for Indian drug ex...
- Uzbekistan can provide more incentives to Indian pharma firms, aims to become regional hub for supplyUzbekistan is inviting Indian drug companies to invest more. They are offering better subsidies and technology help. This aims to make Uzbe...
- 'Wait out IT, buy pharma and defence'; Ajay Bagga's 3-sector playbook for 2026Ajay Bagga offers a clear strategy for Indian markets. He advises waiting for real AI revenue in IT. Pharma remains a strong investment due...
Load More
